Evidence map›Paper›PMID 29216423›Full record

ArticleACS nano2018

Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis.

Xiaoli Wei, Man Ying, Diana Dehaini, Yuanyuan Su, Ashley V Kroll, Jiarong Zhou, Weiwei Gao, Ronnie H Fang, Shu Chien, Liangfang Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaoli WeiDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Man YingDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Diana DehainiDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Yuanyuan SuDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Ashley V KrollDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Jiarong ZhouDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Weiwei GaoDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Ronnie H FangDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Shu ChienDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.
Liangfang ZhangDepartment of NanoEngineering, Department of Bioengineering, and Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.ORCID 0000-0003-0637-0654
University of California San Diego · US

Funding

Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
Chemical Biology Interfaces at UC San DiegoT32GM112584 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2015 to 2019
$729k
NCI NIH HHS R01 CA200574NCI NIH HHS T32 CA153915NIGMS NIH HHS T32 GM112584
6 · The paper itself

Abstract

Cardiovascular disease represents one of the major causes of death across the global population. Atherosclerosis, one of its most common drivers, is characterized by the gradual buildup of arterial plaque over time, which can ultimately lead to life-threatening conditions. Given the impact of the disease on public health, there is a great need for effective and noninvasive imaging modalities that can provide valuable information on its biological underpinnings during development. Here, we leverage the role of platelets in atherogenesis to design nanocarriers capable of targeting multiple biological elements relevant to plaque development. Biomimetic nanoparticles are prepared by coating platelet membrane around a synthetic nanoparticulate core, the product of which is capable of interacting with activated endothelium, foam cells, and collagen. The effects are shown to be exclusive to platelet membrane-coated nanoparticles. These biomimetic nanocarriers are not only capable of efficiently localizing to well-developed atherosclerotic plaque, but can also target subclinical regions of arteries susceptible to plaque formation. Using a commonly employed magnetic resonance imaging contrast agent, live detection is demonstrated using an animal model of atherosclerosis. Ultimately, this strategy may be leveraged to better assess the development of atherosclerosis, offering additional information to help clinicians better manage the disease.

Indexed as

AnimalsAtherosclerosisBiomimetic MaterialsBlood PlateletsCell LineCell MembraneCoated Materials, BiocompatibleFoam CellsHumansHuman Umbilical Vein Endothelial CellsMagnetic Resonance ImagingMiceMice, Inbred C57BLNanoparticlesNanotechnologyOptical ImagingCoated Materials, Biocompatibleatherosclerosisbiointerfacingbiomimetic nanoparticlecardiovascular diseaseMRIplatelet

Identifiers

PMID29216423
PMCPMC5859122
OpenAlexW2771272215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.